ClariVest Asset Management LLC reduced its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 4.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 42,645 shares of the medical research company’s stock after selling 2,027 shares during the quarter. ClariVest Asset Management LLC’s holdings in Genomic Health were worth $2,987,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently bought and sold shares of GHDX. TIAA CREF Investment Management LLC lifted its holdings in shares of Genomic Health by 38.0% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 242,839 shares of the medical research company’s stock valued at $17,052,000 after buying an additional 66,873 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Genomic Health by 144.5% during the 4th quarter. Advisors Asset Management Inc. now owns 12,177 shares of the medical research company’s stock valued at $784,000 after buying an additional 7,196 shares during the period. Rhumbline Advisers lifted its holdings in shares of Genomic Health by 36.7% during the 4th quarter. Rhumbline Advisers now owns 29,707 shares of the medical research company’s stock valued at $1,913,000 after buying an additional 7,974 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Genomic Health by 74.1% during the 4th quarter. SG Americas Securities LLC now owns 8,944 shares of the medical research company’s stock valued at $576,000 after buying an additional 3,807 shares during the period. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Genomic Health by 22.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 24,402 shares of the medical research company’s stock valued at $1,572,000 after buying an additional 4,422 shares during the period. Institutional investors and hedge funds own 95.75% of the company’s stock.
In other Genomic Health news, COO Frederic Pla sold 5,700 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $75.02, for a total value of $427,614.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker sold 270,006 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $74.45, for a total value of $20,101,946.70. The disclosure for this sale can be found here. Insiders sold a total of 1,057,870 shares of company stock valued at $73,788,555 over the last 90 days. 31.30% of the stock is currently owned by company insiders.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. The firm had revenue of $108.80 million during the quarter, compared to analyst estimates of $106.75 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. Genomic Health’s revenue was up 17.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.11) EPS. Sell-side analysts expect that Genomic Health, Inc. will post 1.44 EPS for the current fiscal year.
Several equities analysts have recently weighed in on GHDX shares. ValuEngine raised Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 13th. Zacks Investment Research cut Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Needham & Company LLC reissued a “strong-buy” rating and set a $97.00 price target (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. Deutsche Bank lowered their price target on Genomic Health from $80.00 to $55.00 and set a “hold” rating on the stock in a report on Thursday, May 30th. Finally, BidaskClub cut Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Eleven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $62.63.
COPYRIGHT VIOLATION NOTICE: “ClariVest Asset Management LLC Lowers Stake in Genomic Health, Inc. (NASDAQ:GHDX)” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2019/06/13/clarivest-asset-management-llc-lowers-stake-in-genomic-health-inc-nasdaqghdx.html.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Read More: What is the Coverage Ratio?
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.